Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.

CONCLUSION: Biosimilar and original etanercept showed similar efficacy and safety after the first 6 months of treatment in RA patients from a national registry, which brings further evidence for biosimilarity in unselected patients in real-world setting. PMID: 31668853 [PubMed - as supplied by publisher]
Source: Biologicals : Journal of the International Association of Biological Standardization - Category: Biotechnology Authors: Tags: Biologicals Source Type: research